Andrea Lauter, APRN
Adult Health · New London, CTNPI 1457490070
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by AbbVie at 50.2% of the total. Reporting peaked in 2021 at $10,443 and has fallen 53.3% since, to $4,878 in 2025. Among adult health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 776 payments — averaging $41.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Biogen$2K
- EMD Serono, Inc.$2K
- Novartis$2K
- UCB, Inc.$962
- Lundbeck LLC$953
- plus $8K from 44 others
What the payments were for
- Consulting fees$1,0253%
- Speaking & faculty fees$13,77143%
- Travel & lodging$880%
- Food & beverage$16,87753%
- Education$1360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,897 in reported general payments places this provider in the 95th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 27 | $285,075 |
| AustedoDeutetrabenazine | 24 | $162,035 |
| TecfideraDimethyl Fumarate | 13 | $122,816 |
| Nurtec OdtRimegepant Sulfate | 57 | $120,382 |
| QuliptaAtogepant | 94 | $100,883 |
| VumerityDiroximel Fumarate | 11 | $94,961 |
| UbrelvyUbrogepant | 69 | $94,169 |
| ProvigilModafinil | 20 | $58,609 |
| Emgality PenGalcanezumab-Gnlm | 41 | $47,335 |
| Aimovig AutoinjectorErenumab-Aooe | 37 | $34,762 |
| XcopriCenobamate | 29 | $33,747 |
| BotoxOnabotulinumtoxina | 24 | $28,962 |
| KeppraLevetiracetam | 12 | $23,264 |
| Dimethyl Fumarate | 12 | $21,302 |
| Zolmitriptan | 19 | $16,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy, Botox | $16,024 | $224,014187 claims |
| BiogenTecfidera, Vumerity | $2,160 | $217,77824 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $342 | $162,03524 claims |
| PfizerNurtec Odt, Dilantin | $620 | $131,042103 claims |
| SK Life Science, Inc.Xcopri | $830 | $33,74729 claims |
| Neurelis, Inc.Valtoco | $245 | $11,28515 claims |
| Lilly USA, LLCReyvow | $176 | $8,44111 claims |
| Upsher-smith Laboratories LLCTopiramate | $110 | $2,823165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 adult health providers in Connecticut.
Other adult health in New London
- Adam TwicklerNew London$8K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Megan CarlucciManchester$28K
- Kellie HaleNew Haven$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.